[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354327-105":59,"doc-detail-354327-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-safety-of-biologic-agents-and-targeted-therapies-in-immune-mediated-inflammatory-arthritides-2026-review","Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides - 2026 Review","","Immune-mediated inflammatory arthritides (IMIA) are chronic immune-driven diseases where long-term malignancy safety increasingly shapes therapeutic decisions. Patients are not cancer-neutral at baseline: persistent inflammation, smoking exposure, age, and cumulative immunosuppressive treatment modify cancer susceptibility. This narrative review synthesizes evidence on tumor safety across major biologic drug classes and Janus kinase inhibitors, highlighting most biologics as broadly reassuring and identifying non-melanoma skin cancer as a consistent signal. JAK inhibitors require greater caution in risk-enriched populations, with updated guidance emphasizing individualized, risk-stratified therapy after cancer remission.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-safety-of-biologic-agents-and-targeted-therapies-in-immune-mediated-inflammatory-arthritides-2026-review/354327/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-safety-of-biologic-agents-and-targeted-therapies-in-immune-mediated-inflammatory-arthritides-2026-review/354327.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which IMIA conditions are covered in this review?","Question",{"text":112,"@type":113},"The review covers rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, emphasizing shared immune pathways with distinct clinical features and treatment responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the most consistently reported treatment-associated cancer signal?",{"text":117,"@type":113},"Non-melanoma skin cancer is described as the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do JAK inhibitors require additional caution?",{"text":121,"@type":113},"JAK inhibitors show higher concern for malignancy risk in risk-enriched rheumatoid arthritis populations, especially older patients, smokers, and those with prior malignancy or prolonged treatment exposure.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354327,1790917091,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 04 June 2026  \nDOI 10.3389/fimmu.2026.1827981  \nOPEN ACCESS  \nEDITED BY  \nAlenka Gagro,  \nChildren ’s Hospital Zagreb, Croatia  \nREVIEWED BY  \nAlexa Meara,  \nThe Ohio State University, United States Nicola Jane Gullick,  \nUniversity Hospitals Coventry and Warwickshire NHS Trust, United Kingdom  \n*CORRESPONDENCE  \nSheng-Guang Li  \n [lishengguang@vip.163.com](lishengguang@vip.163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 11 March 2026  \nREVISED 20 May 2026  \nACCEPTED 22 May 2026  \nPUBLISHED 04 June 2026  \nCITATION  \nLi S-G, Zou Y, Li J, Zhang L, Zhang J, Long T, Yu R and Zhang Y (2026) Tumor safety of biologic agents and targeted therapies in immune-mediated inﬂammatory arthritides.  \nFront. Immunol. 17:1827981 .  \ndoi: 10.3389/fimmu.2026.1827981  \nCOPYRIGHT  \n© 2026 Li, Zou, Li, Zhang, Zhang, Long, Yu and Zhang. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTumor safety of biologic agents and targeted therapies in immune-mediated inﬂammatory arthritides  \nSheng-Guang Li *†, Yadan Zou †, Ji Li †, Lina Zhang, Jing Zhang, Ting Long, Ruohan Yu and Yanfeng Zhang  \nDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China  \nImmune-mediated inﬂammatory arthritides (IMIA), including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, are chronic immune-driven disorders in which long-term malignancy safety has become a key determinant of therapeutic decision-making. Patients with IMIAare not oncologically neutral at baseline; persistent inﬂammatory burden, smoking exposure, age, and cumulative immunosuppressive treatment all modify cancer susceptibility. Against this background, biologic and targeted synthetic diseasemodifying antirheumatic drugs may both reduce inﬂammation-associated oncogenic pressure and attenuate antitumor immune surveillance. In this narrative review, we synthesize current evidence on tumor safety across major biologic classes and Janus kinase inhibitors, with emphasis on data emerging through early 2026. Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable proﬁle inpatients with prior lymphoproliferative disease, whereas IL-6 and IL-17/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets. By contrast, JAK inhibitors require greater caution in risk-enriched rheumatoid arthritis populations, especially older patients, smokers, and those with prior malignancy or prolonged treatment exposure. Recent register-based studies have shown that overall cancer incidence with JAK inhibitors is comparable to that with TNF inhibitors, although lung and keratinocyte cancers occur more frequently in certain risk groups; accordingly, updated 2025 EULAR guidance recommends early initiation of targeted therapy after cancer remission and tailoring drug choice to prior cancer type and patient-speciﬁc factors. We further examine tumor-type-speciﬁc patterns, major modiﬁers of risk, and practical riskstratiﬁed management strategies. The central clinical message is that malignancy safety in IMIA should be interpreted through an individualized framework that balances inﬂammatory control against oncologic vulnerability rather than through uniform class-based avoidance.  \nKEYWORDS  \naxial spondyloarthritis, biologic DMARDs, ca","cbCaim56NZwDF7sr","https://ap.wps.com/l/cbCaim56NZwDF7sr","pdf",2596174,"English","# Introduction\n## Malignancy safety in IMIA as a major management issue","[{\"question\":\"Which IMIA conditions are covered in this review?\",\"answer\":\"The review covers rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, emphasizing shared immune pathways with distinct clinical features and treatment responses.\"},{\"question\":\"What is the most consistently reported treatment-associated cancer signal?\",\"answer\":\"Non-melanoma skin cancer is described as the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept.\"},{\"question\":\"Why do JAK inhibitors require additional caution?\",\"answer\":\"JAK inhibitors show higher concern for malignancy risk in risk-enriched rheumatoid arthritis populations, especially older patients, smokers, and those with prior malignancy or prolonged treatment exposure.\"}]","Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides - 2026 Review | PDF",1790110106,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fbb652332ba86f65367fdeb998bfeae.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a1694673ae162f247bd108c410d61d3.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e68ceaa5120ad99f3df5084ce9d8c4d5.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5635d6eba9847c46e5bfb6e366dc603.webp",980,1385]